Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07190209 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Study acronym: PERSEPHONE
StatusRecruiting
PhasePhase 3
SponsorSanofi
Started2025-09-16
View on ClinicalTrials.gov ↗
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.

Amendment history 4 changes detected by DataLookout

2026-06-16
Trial sites expanded: 196 → 215 locations
2026-05-28
Trial sites expanded: 183 → 196 locations
2026-05-09
Trial sites expanded: 166 → 183 locations
2026-04-22
Trial sites expanded: 153 → 166 locations
Trial Details
NCT Number NCT07190209
Lead Sponsor Sanofi
Conditions Chronic Obstructive Pulmonary Disease
Enrollment 942 participants
Start Date 2025-09-16
Primary Completion 2029-11-27 (estimated)
Study Completion 2030-01-22 (estimated)
Updated on ClinicalTrials.gov 2026-09-02